首页> 外文期刊>Experimental Animals >Effect of Human Erythropoietin (hEPO) Treatment on Anemia in ICR-derived Glomerulonephritis (ICGN) Mice
【24h】

Effect of Human Erythropoietin (hEPO) Treatment on Anemia in ICR-derived Glomerulonephritis (ICGN) Mice

机译:人类促红细胞生成素(hEPO)治疗对ICR衍生的肾小球肾炎(ICGN)小鼠贫血的影响

获取原文
获取原文并翻译 | 示例
       

摘要

ICR-derived glomerulonephritis (ICGN) mice are a novel inbred strain with hereditary nephrotic syndrome and are thus considered a good animal model of human idiopathic nephrotic syndrome. In the present study, we investigated the effect to erythrocyte production by human erythropoietin (hEPO) treatment in ICGN mice during the early nephrotic stage. Erythrocyte count, hemoglobin concentration and hematocrit value in hEPO-treated (5 U/body/day, for 5 days) ICGN mice were recovered to the levels found in normal ICR mice. In addition, there was no correlation between plasma creatinine level, a marker of renal function, and erythrocyte count after hEPO treatment. Therefore, anemia in ICGN mice may be caused by decreased production of EPO in the kidney following progressive parenchymal damage.
机译:ICR衍生的肾小球肾炎(ICGN)小鼠是具有遗传性肾病综合征的新型近交系,因此被认为是人类特发性肾病综合征的良好动物模型。在本研究中,我们调查了早期肾病阶段ICGN小鼠中人促红细胞生成素(hEPO)处理对红细胞产生的影响。将经hEPO处理(5 U /人/天,连续5天)的ICGN小鼠中的红细胞计数,血红蛋白浓度和血细胞比容值恢复到正常ICR小鼠中发现的水平。此外,hEPO治疗后血浆肌酐水平,肾功能标志和红细胞计数之间没有相关性。因此,ICGN小鼠中的贫血可能是由进行性实质损害后肾脏中EPO的生成减少所致。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号